Campbell, Katherine E.
Gorelik, Alexandra
Szoeke, Cassandra E.
Dennerstein, Lorraine
Funding for this research was provided by:
National Health and Medical Research Council (547600, 103350, 1062133)
Ramaciotti Foundation (NA)
Alzheimer’s Association (NIA320312)
Article History
Received: 2 July 2019
Accepted: 17 February 2020
First Online: 4 March 2020
Ethics approval and consent to participate
: This study was approved by the University of Melbourne Human Research Ethics Committee (HREC:931149X, 1034765, 1105251 & 750632.1), and all participants provided written informed consent. Participants did not receive a stipend for participating in this study. The study was conducted in accordance with the National Health and Medical Council Ethical Conduct in Human Research and Declaration of Helsinki. Authors’ disclosures available online (ExternalRef removed). All women have provided written consent for each time point in which they have participated.
: Not applicable.
: KEC, LD and AG report no conflict of interest. CS has provided clinical consultancy and been on scientific advisory committees for the Australian Commonwealth Scientific and Industrial Research Organisation, Alzheimer’s Australia, University of Melbourne and other relationships which are subject to confidentiality clauses. She has been a named Chief Investigator on investigator driven collaborative research projects in partnership with Pfizer, Merck, Bayer and GE. She has been an investigator on clinical trials with Lundbeck within the last 2 years. The Healthy Ageing Program has received support from National Health and Medical Research Council, Alzheimer’s Association, Collier Trust, Scobie and Claire Mackinnon Foundation, JO and JR Wicking Trust, Shepherd Foundation, Brain Foundation, Mason Foundation, Ramaciotti Foundation, Alzheimer’s Australia, and The Royal Australian College of Physicians. She may accrue revenues from patent in pharmacogenomics prediction of seizure recurrence.